Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
HAE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$47.32 - $94.99
Previous CloseN/A
Volume53.78K
Average Volume (3M)994.96K
Market Cap
$2.46B
Enterprise Value$4.50B
Total Cash (Recent Filing)$292.90M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)15.3
Beta0.76
Next Earnings
Nov 06, 2025EPS Estimate
1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.10
Shares Outstanding48,177,258
10 Day Avg. Volume810,041
30 Day Avg. Volume994,963
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap1.83
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda12.99
Forecast
1Y Price Target
$73.13Price Target Upside45.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHaemonetics generated $321.4 million in revenue, which exceeded both the internal estimate and the consensus estimate.
Market PositionThe company is capturing meaningful share with key fractionator customer, Biolife, and maintains a strong relationship with industry giant, Grifols.
Bears Say
Competitive ChallengesHaemonetics lost material market share in around 50 of its 500 key EP hospital accounts due to aggressive competition.
Product PortfolioThe downgrade to a Neutral rating reflects limited confidence in the product portfolio and growth trajectory.
Haemonetics News
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $47.31 and its highest was $94.98 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Haemonetics Corp.’s market cap is $2.46B.
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Nov 06, 2025 which is in 26 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Aug 07, 2025. The company reported $1.1 earnings per share for the quarter, beating the consensus estimate of $1.008 by $0.092.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is 1.11.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 48,177,258 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.1 in its last earnings report, beating expectations of $1.008. Following the earnings report the stock price went down -26.58%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Currently, no hedge funds are holding shares in HAE
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.13 (45.82% Upside)
$73.13 (45.82% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 93.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.10%
12-Months-Change
Fundamentals
Return on Equity
18.27%
Trailing 12-Months
Asset Growth
-3.10%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
HAE Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong performance in key growth areas, particularly in the plasma and hemostasis management segments, with significant margin expansion and strategic share buybacks contributing to earnings growth. However, challenges remain in the interventional technologies and overall revenue declined due to portfolio transitions. The company is optimistic about overcoming these challenges with strategic initiatives.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$73.13
▲(45.82% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
41.43% Mutual Funds
30.85% Other Institutional Investors
0.88% Public Companies and Individual Investors